Gilead Sciences Inc at Jefferies Healthcare Conference Transcript
Thank you very much. I want to get started on the next session. I'm Michael Yee, Managing Director and Senior Biotechnology Analyst at Jefferies. I'm very happy to have with us here at Gilead Sciences, Johanna Mercier, the Chief Commercial Officer. And I thought, that would be quite perfect timing because we're coming away from ASCO. We were just talking about flying from Chicago over here to New York.
Questions & Answers
And, a lot of developments going on in oncology for Gilead as well as, obviously, I want to spend half of this talking about the developments in HIV and all the long-acting developments, which I think is getting a lot more news because some of your competitors are talking about long-acting as well, and I think that's underappreciated.
So maybe, just in the first half of our discussion, we have come away from ASCO, and Gilead is obviously knee-deep in breast cancer with Trodelvy, and
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
